Results 121 to 130 of about 72,674 (159)
Some of the next articles are maybe not open access.

Medical Management of CML

Hematology, 2007
AbstractManagement strategies of patients with chronic-phase chronic myeloid leukemia (CML) have been revolutionized by the BCR-ABL–selective kinase inhibitor imatinib, which is substantially improving median survival. However, a proportion of patients suffer progressive disease on imatinib therapy.
openaire   +2 more sources

Treatment strategies for CML

Best Practice & Research Clinical Haematology, 2009
Little important progress was made in terms of prolongation of life for patients with chronic myeloid leukaemia (CML) until the advent of interferon-alpha and allogeneic stem cell transplantation in the 1980s. However, in 1998 the introduction of imatinib, the first tyrosine kinase inhibitor (TKI) that specifically targets the BCR-ABL1 oncoprotein, has
openaire   +2 more sources

CML

2011
Guy L. Steele   +60 more
  +4 more sources

Double trouble for CML

Science Translational Medicine, 2017
Combining two BCR-ABL1 inhibitors with nonoverlapping mechanisms of action eradicates CML and prevents recurrence.
openaire   +2 more sources

CML

Oncology Times, 2014
  +4 more sources

CML in pregnancy and childhood

Best Practice & Research Clinical Haematology, 2009
With the improved survivals offered by the tyrosine kinase inhibitors has come the necessity to address issues relating to quality of life and one such area is that of fertility and parenting. Animal data suggest that imatinib at standard dosages is unlikely to impair fertility in either adult males or females but human data remain limited.
openaire   +2 more sources

Comparison of the Transcriptomic Signatures in Pediatric and Adult CML

Cancers, 2021
Jason Gotlib   +2 more
exaly  

CML

Oncology Times, 2007
openaire   +1 more source

CML

ACM SIGPLAN Notices, 1991
openaire   +1 more source

Home - About - Disclaimer - Privacy